Source - SMW
Premaitha Health said it had secured the right to appeal a judgement in its ongoing patent litigation with Illumina and others.

"The court was refreshingly pragmatic in granting us leave to appeal all aspects of the November judgment, with which we still strongly disagree," chief executive Stephen Little said.

"We had anticipated an interim costs award and had taken steps to prepare the necessary facility to meet that, for which we are very appreciative of Thermo Fisher's recent financial support."

"We anticipate the appeal cycle will take at least 12 months and the costs will be significantly lower than those we have incurred to date. We remain hopeful that the courts will in time agree with us on the patent issues at hand."

 


At 10:03am: (LON:NIPT) Premaitha Health Plc share price was +0.25p at 4.75p